Last $70.07 USD
Change Today +1.06 / 1.54%
Volume 1.3M
STJ On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 8:04 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

st jude medical inc (STJ) Snapshot

Open
$69.00
Previous Close
$69.01
Day High
$70.15
Day Low
$68.79
52 Week High
07/7/14 - $71.90
52 Week Low
07/12/13 - $47.77
Market Cap
19.9B
Average Volume 10 Days
1.7M
EPS TTM
$3.77
Shares Outstanding
284.2M
EX-Date
06/26/14
P/E TM
18.6x
Dividend
$1.08
Dividend Yield
1.48%
Current Stock Chart for ST JUDE MEDICAL INC (STJ)

st jude medical inc (STJ) Related Businessweek News

View More BusinessWeek News

st jude medical inc (STJ) Details

St. Jude Medical, Inc. develops, manufactures and distributes medical devices for cardiac rhythm management, cardiovascular, and atrial fibrillation therapy areas worldwide. It operates in two divisions, Implantable Electronic Systems, and Cardiovascular and Ablation Technologies. The company offers tachycardia implantable cardioverter defibrillator systems that provide therapy to patients suffering from heart conditions, such as sudden cardiac arrest; and cardiac resynchronization therapy devices to treat patients suffering from heart failure. It also provides pacemakers for patients whose hearts beat too slowly or who suffer from other cardiac arrhythmias; leads to carry electrical impulses to the heart and provide information from the heart to the device; and programmers and remote monitoring equipment, which are used by physicians and healthcare professionals to program cardiac rhythm management devices and analyze device data to enhance patient management. In addition, the company offers vascular closure devices, compression assist devices, pressure measurement guidewires, diagnostic coronary imaging technology, vascular plugs, percutaneous catheter introducers, and diagnostic guidewires; and transcatheter aortic heart valves, heart valve repair and replacement products, and transcatheter structural heart defect devices. Further, it provides electrophysiology introducers and catheters, and ablation systems, as well as cardiac mapping, navigation, and recording systems for diagnosing and treating various irregular heart rhythms. Additionally, the company offers neurostimulation systems for chronic pain, such as rechargeable and primary cell implantable pulse generators. The company sells its products through direct sales force and independent distributors. St. Jude Medical, Inc. was founded in 1976 and is headquartered in Saint Paul, Minnesota.

16,000 Employees
Last Reported Date: 02/26/14
Founded in 1976

st jude medical inc (STJ) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.0M
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $430.0K
Chief Operating Officer
Total Annual Compensation: $730.0K
President of International Division
Total Annual Compensation: $752.4K
Executive Vice President
Total Annual Compensation: $730.0K
Compensation as of Fiscal Year 2013.

st jude medical inc (STJ) Key Developments

St. Jude Medical Inc. Presents at Goldman Sachs 35th Annual Global Healthcare Conference, Jun-11-2014 08:40 AM

St. Jude Medical Inc. Presents at Goldman Sachs 35th Annual Global Healthcare Conference, Jun-11-2014 08:40 AM. Venue: Terranea Resort in Rancho Palos Verdes, 100 Terranea Way, Los Angeles, California, United States. Speakers: Eric S. Fain, Group President.

St. Jude Medical, Inc. and CardioMEMS Announces U.S. Food and Drug Administration Approval of the CardioMEMS HF System

St. Jude Medical, Inc. and CardioMEMS announced U.S. Food and Drug Administration (FDA) approval of the CardioMEMS HF System. The CardioMEMS HF System is the first and only FDA-approved heart failure monitoring device that has been proven to significantly reduce HF hospital admissions when used by physicians to manage heart failure. The CardioMEMS HF System uses a miniaturized, wireless monitoring sensor that is implanted in the pulmonary artery. The CardioMEMS HF System uses a miniaturized, wireless monitoring sensor that is implanted in the pulmonary artery (PA) during a minimally invasive procedure to directly measure PA pressure. Directly measuring PA pressure via a procedure called a right-heart catheterization is a standard-of-care practice for managing worsening HF in patients who have been hospitalized. The CardioMEMS HF System allows patients to transmit the same information from their homes to their health care providers allowing for personalized and proactive management to reduce the likelihood of hospitalization. Heart failure occurs when the heart is unable to pump enough blood to meet the body's demands and blood pressure within the heart is elevated. Significant HF progression over a period of days is known as acute decompensation and leads to hospitalization. Increased PA pressures often precede indirect measures of worsening HF such as weight and blood pressure changes. The CardioMEMS HF System allows clinicians to stabilize PA pressures by proactively managing medications and other treatment options while also providing an early indication of worsening HF.

St. Jude Medical Announces First Implants in US Study of the Portico Transcatheter Aortic Heart Valve System

St. Jude Medical Inc. announced that the first patient implants occurred in the Portico(TM) Re-sheathable Transcatheter Aortic Valve System U.S. IDE Trial (PORTICO trial). The trial is evaluating the Portico(TM) Transcatheter Aortic Valve System, the first aortic heart valve that is repositionable until fully deployed. The trial will enroll patients who are considered to have a high or an extreme surgical risk (meaning they would not be considered) for open-heart surgery. The Portico(TM) Transcatheter Aortic Heart Valve is being evaluated in a clinical study. Caution: Investigational device. Limited by Federal (or United States) law to investigational use. Photo provided by St. Jude Medical. The PORTICO trial is evaluating the Portico valve and delivery system in patients with symptomatic severe aortic stenosis -- a narrowing of the aortic valve that significantly impedes blood from flowing out of the heart. During transcatheter aortic valve replacement (TAVR) procedures, a Portico heart valve is delivered via a catheter using either a transfemoral (through the artery in the leg) or an alternative access approach in order to gain access to the heart. The Portico valve is positioned in the patient's heart as it continues to beat, alleviating the need for cardiopulmonary bypass, where a machine takes over a patient's heart and lung function. Patients are evaluated by a heart team consisting of a cardiac surgeon and an interventional cardiologist. The first implants in the PORTICO trial were conducted the same day on opposite coasts of the U.S. One operating team comprised of Dr. Raj Makkar, director of Interventional Cardiology, and Dr. Wen Cheng, cardiothoracic surgeon and program director of the Thoracic Surgery Residency Program performed a Portico TAVR procedure at Cedars-Sinai Heart Institute in Los Angeles. The other operating team was comprised of Dr. Gregory P. Fontana, cardiac surgeon and chairman of the department of cardiothoracic surgery and Dr. Carlos Ruiz, an interventional cardiologist at Lenox Hill Hospital in New York City. Drs. Fontana and Makkar serve as co-principal investigators for the PORTICO trial.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STJ:US $70.07 USD +1.06

STJ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Boston Scientific Corp $13.29 USD +0.19
Coloplast A/S kr478.90 DKK +3.60
Smith & Nephew PLC 1,020 GBp +3.00
Terumo Corp ¥2,232 JPY -32.00
Zimmer Holdings Inc $103.79 USD +0.12
View Industry Companies
 

Industry Analysis

STJ

Industry Average

Valuation STJ Industry Range
Price/Earnings 27.2x
Price/Sales 3.6x
Price/Book 4.9x
Price/Cash Flow 26.6x
TEV/Sales 2.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ST JUDE MEDICAL INC, please visit www.sjm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.